| Line Item | 2024-03-31 | Y/Y |
|---|---|---|
| R&D Expense | $212.9M | +32.9% |
| SG&A Expense | $57.3M | +19.3% |
| Pre-tax Income | -$258.8M | -22.7% |
| Income Tax | $567K | +6200.0% |
| Net Income | -$259.3M | -22.9% |
| EPS (Basic) | -$1.88 | -9.9% |
| EPS (Diluted) | -$1.88 | -9.9% |
| Line Item | 2024-03-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $635.4M | +68.7% |
| Accounts Receivable | $5.3M | +662.4% |
| Current Assets | $665.8M | +64.7% |
| Total Assets | $666.4M | +64.2% |
| Current Liabilities | $48.6M | +12.3% |
| Total Liabilities | $48.6M | +12.1% |
| Stockholders' Equity | $617.8M | +70.4% |
| Line Item | 2024-03-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$214.2M | -13.8% |
| Capital Expenditures | $360K | +82.7% |
| Investing Cash Flow | -$360K | -82.7% |
| Financing Cash Flow | $472.4M | +566.5% |
| Free Cash Flow | -$214.6M | -13.9% |